Month: September 2011

Research on Down syndrome and Alzheimers disease continues its advance.

|

Research on Down syndrome and Alzheimer’s disease continues its advance.

21 September day world of Alzheimer’s.

-el Dr. Javier García Alba, Professor in the Department of evolutionary psychology and of education of the Faculty of education (UCM) points to the importance of having test for cognitive assessments of persons with Down’s syndrome

Madrid, 2011-September last and recent studies in the period 2009-2011 by different research teamssome of the own Foundation syndrome of Down from Madrid (FSDM), have led to a series of advances in knowledge of Alzheimer’s disease in people with Down syndrome.

As explained by Dr. García Alba, there are signs of presence of the neuropathology of from relatively early stage Alzheimer’s disease in Down syndrome. However, this does not mean that all people with Down Syndrome will necessarily present the disease clinic.

It has also clarified that it had noted that “ there is a greater number of people with Alzheimer’s disease affected Down syndrome and early onset ”. However, there are discrepancies in the percentages of people with Down syndrome suffer from this disease. These discrepancies are related to the possibility of issuing false diagnoses. In this sense, García Alba has pointed out that “ the cognitive impairment that can occur when some people do not always is due to the effects of Alzheimer’s disease, since there are other pathologies involving such impairment ”.

The conclusions drawn from recent studies include: the interest in creating evidence to make good Diagnostics and detect early stages of Alzheimer’s disease, as well as the line of genetic research to discover new drugs, with the effect of delaying the progression of the disease and mitigate its symptoms in cognitive impairment.

For its part, the Foundation syndrome of Down in Madrid (FSDM) maintains the support “ total ” in relation to the projects and studies carried out to advance research on Down syndrome.

The syndrome Madrid Down Foundation (FSDM) was established in 1989 as a not-for-profit entity whose mission is: promote, develop and promote all kinds of activities aimed at the full family, school, employment and social integration of persons with intellectual disabilities and Down syndrome in order to improve the quality of life of this group and their families.

Read More

Genetics, one of the keys to the prognosis of progression of osteoarthritis.

|

Genetics, one of the keys to the prognosis of progression of osteoarthritis.

World Congress of osteoarthritis (OARSI).

-Bioiberica leads the project Arthrosischip to predict the evolution of the osteoarthritis of knee with an analysis of saliva

-Francisco j. Blanco Garcia, rheumatologist complex Hospitalario Universitario A Coruña, has presented at the OARSI databases of research, with the collaboration of 32 hospital centres of all Spain

Barcelona, 2011-September the study of the genetics of arthritis offers new fields of research on the forecast and the progression of osteoarthritis of the knee. So this weekend in arthrosis OARSI World Congress, held in San Diego (California), in which Bioiberica has introduced the Arthrosischip to predict the evolution of arthritis from a saliva sample has been exposed.

Arthritis is a disease with a strong genetic component in its development and progression. On some problems of osteoarthritis, genetic inheritance reaches between 60% and 70% of cases. This evidence has laid the basis of the investigation led by Bioiberica and expounded by Dr. Francisco j. Blanco, rheumatologist of the complex Hospitalario Universitario A Coruña, in the World Congress of osteoarthritis.

Dr. Francisco j. Blanco explained that arthritis is a poligenética disease with multiple interactions between genes. He also mentioned that genetic material can be found in the nucleus of the condrocitos both mitochondria and that such genetic material plays an important role in the development of the disease. In this way, different mitochondrial DNA haplogroups may have different phenotypes artrósicos and
probability of progression.

On the basis of these claims is developing the project Arthrosischip, to create a tool that combines clinical and genetic data (DNA chip) allowing to predict the progression of primary osteoarthritis of the knee in patients previously diagnosed the disease and to customize your treatment as well as predict the risk of implantation of prosthesis in such patients. Based on the technology of DNA microarrays, Arthrosischip shall consist of a genetic analysis from a saliva sample that could identify those genetic mutations associated with the progression of arthritis that are significant and clinical data, basically, risk factors such as sexthe IMC or concomitant diseases such as diabetes. Dr. White also explained the design of the trial (multicenter retrospective) which is currently in the final stage of the recruitment of samples.

It is a study jointly developed between Bioiberica, company with more than 30 years of experience in health of joints and leader in chondroprotection, and Progenika, specialist in the design and development of tools for personalized medicine. In it, involved 32 hospital centres of all Spain.

The OARSI in Barcelona in April 2012

With Bioiberica as one of the major sponsors, the next edition of OARSI will take place in Barcelona in April. During these days will gather in the city more than one thousand of specialists from around the world, including rheumatologists, researchers, orthopaedic surgeons, radiologists, clinical and other stakeholders in the research of arthritis. However, this Congress has the most prestigious professionals dedicated to the treatment of arthritis to share progress and experiences in the investigation of this disease. Why Barcelona and Spain will become one week the world headquarters of arthritis.

Bioiberica Farma

Bioiberica Farma is the only Spanish laboratory specializing in research and development of effective drugs for the treatment of osteoarthritis. Specifically, specialises in chondroprotection, namely, prevention, diagnosis and treatment of cartilage, synovial membrane, and the subcondral bone injuries.

This expertise in the treatment of osteoarthritis has helped Bioiberica Farma occupies a leading position endorsed by numerous published clinical trials, research projects underway, the recognition of different societies scientific and medical, strict quality control chemical and biological production processes, the quality of their products and editing of publications specialised in chondroprotection.

Read More

There was an error deserializing the object of type System.String. Encountered unexpected character l.

|

“Lacer Farma” leads a research to prevent disease cerebrovascular.

-the study, conducted in collaboration with the Group Neurovascular research at the Cajal Institute of the CSIC, elaborates on the mechanisms of self-defense that launches the central nervous system diseases such as Alzheimer’s and stroke cerebrovascular

– ‘ Lacer Farma ’ working on a molecule with vasodilator action, proangiogénica and antiapoptótica

Barcelona, 2011-September LA419, discovered and patented molecule by ‘ Lacer Farma ’, specialist in the cardiovascular field, could have protective and repair effects against cerebrovascular diseases such as stroke and Alzheimer’s disease, according to the preliminary results of the study being carried out between the Department’s r & d Pharma of laboratories Lacer directed by DRA. Marisabel Mourelle and the research group of the Department of Molecular Neurobiology at the Cajal Institute of the CSIC, directed by the prestigious researcher Dr. Ricardo Martinez-Murillo. The purpose of the investigation, which began a year ago, is to identify new applications of this molecule with vasodilator action, pro-angiogenic (allows the formation of blood vessels from pre-existing vessels) and antiapoptótica (prevents cell death) to prevent Neurovascular diseases and mitigate its effects.

Both stroke and Alzheimer’s disease are two cerebrovascular disease serious each year reaching an important population group. The stroke is the leading cause of death among women in Spain, – affects one in every seven – and the second among the general population and every year suffer to 130,000 people, of which 8,000 die or are disabled, according to the national register of stroke drawn up by the Group of study of disease stroke of the Spanish Neurology Society (GEECV-SEN). The World Health Organization (who) data show that these diseases already represent the third cause of death in the Western world, the physical disability in adults first and the second of dementia. WHO estimates suggest that over the next 15 years the incidence of stroke in the world’s population will increase by 27%.

Investigations allow promising expectations on new applications of the LA419 molecule, whose effectiveness has been demonstrated in the treatment of cardiovascular diseases.

In the case of the stroke, the administration of the molecule could have a preventive effect against disease and act as therapeutic agent in their treatment. Thus established the first results of the study in laboratory, suggest that the administration of the molecule 15 minutes later stroke reduces significantly the volume of vascular edema, which would enable a very significant reduction of neurological sequelae disabling arising from the stroke. Tests carried out have shown that the molecule, which has antithrombotic properties and antiisquémicas (prevents the decrease of blood flow), does not alter the blood pressure, so it is emerging as a possible therapeutic agent in the treatment of stroke.

In relation to Alzheimer’s disease, a process hitherto incurable neurodegenerative disease, researchers are analysing the potential effects of the LA419 molecule on the ability of learning and memory in experimental disease model animals. Because of its recognized antioxidant properties, the molecule can trap and inactivate free radicals and other oxidizing substances that damage cell membranes and causing, in the case of neurons, brain aging. The research aims to determine the possibilities of therapeutic use of this product through preclinical studies that are underway. In Spain, Alzheimer’s disease affects between 650,000 and 800,000 people, according to the Alzheimer’s Foundation. The report submitted in July in the Alzheimer Association International Conference concludes, after cancer, Alzheimer’s is the disease most feared by the Spanish.

About

DRA. Marisabel Mourelle Mancini. PhD in pharmacology by the Centre for research and advanced studies of the National Polytechnic Institute of Mexico (CINVESTAV) and head of the Department’s r & d & innovation laboratories Lacer. It is creative in 16 patents of new chemical entities, such as pain relievers or new molecules with antidiabetic activity, among others. Author of hundreds of publications in international scientific journals ‘ Circulation ’, ‘ Hypertension ’ and ‘ Gastroenterology ’, has participated in numerous conferences in congresses and scientific forums.

Dr. Ricardo Martínez Murillo. Doctor of medicine from the Universidad Complutense de Madrid and neurobiologist. Head of the Neurovascular research group in the Department of Molecular Neurobiology, cellular and the development of the Higher Council of scientific research (CSIC) in the Cajal Institute. Its main lines of research revolve around processes Neuropathological as cerebral ischemia and Alzheimer’s disease. He is the author of hundreds of publications in international journals such as ‘ Neuroscience ’, ‘ Brain Research ’ or ‘ Journal of Neuroscience Research ’; He has directed more than 30 research projects and has participated in numerous conferences in congresses and scientific forums.

Read More

Analysis laboratories opt for the national LIMS platform.

|

Analysis laboratories opt for the LIMS platform national.

Spain, 2011-September at present LIMS systems are determinants in the management of laboratories of research and analysis, as this technology offers a suite of solutions that can optimize and manage processes request, analysis, traceability and economic management of centres to support research in universities and r & d.

The platform @ LIMS provides the features that currently demand centres of r & d, universities and laboratories for analysis of our country and is able to combine technical and economic management in a single tool, which explains its growing demand.

According to Juan Carlos García Chillón, Alatel director, “ modernization management who are experiencing academic institutions and r & d, requires the implementation of tools that they are adapting to new needs and environments, and consistent with the standards of excellence that is headed the so-called knowledge society. Such is the case of the pilot plant of fine chemistry at the University of Alcalá and the research technical services of the universities autonomous of Madrid, Alicante and Extremadura, who have developed their LIMS with Alatel platform ”.

Read More

Epilepsy experts meet to deepen in the study of Zebinix (R).

|

Epilepsy experts met to deepen in the study of Zebinix r.

-in Spain, it is estimated that about 400,000 people suffering from epilepsy. Each year are diagnosed more than 20,000 new cases (1)

-the progress achieved in recent years in the treatment of the disease and the development of new drugs with better tolerability have improved the quality of life of the patient

-the best way of “ ahead of ” to the crisis is taking antiepileptic medication correctly, because decreases neuronal hiperexcitabilidad. With antiepileptic drugs, the crisis come to control 70% of patients

-Zebinix ®, is the first drug research from Bial, which is administered by mouth – a compressed journal-allow better enforcement and one has a good tolerability in patients with epilepsy (2,3)

-pharmaceutical company Bial is strongly committed to innovation terapéutica, investing more than 20% of its annual turnover in I & D

Porto, 2011-September Zebinix ® has gathered these days at the headquarters of Bial in Oporto, prestigious epileptólogos and national and international, neuroscientists in order that can share experiences and exchange views relating to progress in the treatment of epilepsy.

Epilepsy is a neurological disease that affects approximately 400,000 Spanish and each year are diagnosed more than 20,000 new cases according to the Spanish Foundation of neurological diseases study FEEN.

Within the framework of this meeting, experts discuss various aspects related to the treatment and disease progression and will share his experience on the effectiveness of treatments in the short and long term, improvements in the quality of life of patients with new drugs and will reflect on the experience with the epilepsy in Europe and Portugal.

According to the DRA. Sea Carreño, Director of the epilepsy unit of the Hospital Clínic of Barcelona and attending the meeting, “ these meetings help neurologists that we dedicate ourselves to epilepsy to have knowledge of the developments in the treatment of the disease that can be enhanced for our patients. They are also a very appropriate framework for sharing preliminary experiences with new drugs or other forms of therapy ”.

Advances in the treatment of epilepsy

Attendees to the meeting experts point out that the progress achieved in recent years in the treatment of epilepsy and the development of new drugs with better tolerability have improved the quality of life of patients.

“ If crises are well controlled and the medication is well tolerated, there is usually no significant impact on the quality of life. However, the drug-resistant epilepsy is associated with a poor quality of life by the crisis itself and the problematic associate (cognitive, psychiatric, social, and labor) ”, explains this specialist. According to Dr. Carreño, now “ we recognize and better treat this pathology ”

with respect to the consequences that may occur in the short- and long-term epilepsy DRA. Carreño points out that “ there are many sick people with epilepsy that lead a completely normal life even if they have to take medication. However, some patients, especially those who have frequent crises which are not controlled with medication, may have social and labour issues. The serious long-term epilepsy may also be associated with cognitive problems (e.g. alteration of memory), psychiatric (depression and anxiety) and increase mortality ”.

“ The best way of “ ahead ” to crises is correctly taking antiepileptic medication, because it decreases the neural hiperexcitabilidad. With antiepileptic drugs come to control 70% of patients ”, emphasizes the DRA. Carreño.

Zebinix ® promising treatment in the treatment of epilepsy

In this sense, BIAL, co-promotion with Eisai Europe, a subsidiary of the Japanese multinational Eisai, recently launched, Zebinix ® (eslicarbazepina acetate), an antiepileptic drug (AED) administered orally – a daily pill – and is effective to improve seizure control.

With regard to the benefits that presents eslicarbazepina, Dr. acetate Carreño points out that “ Zebinix ® is a drug in clinical trials has proven to be effective for the treatment of rebel crisis, with a good tolerability profile. In addition its pharmacokinetics allows only takes a day, which represents a great advantage for many patients ”, says the DRA. Carreño.

Zebinix ® is the first drug of BIAL, one of the most important Iberian pharmaceutical groups, research, and is the fruit of 14 years of research and investment of 300 million euros.

This new drug was approved in April 2009 by the European Commission – based on the opinion of the European Medicines Agency – as adjunctive therapy in adults with partial seizures with or without secondary generalization.

On BIAL

Founded in 1924, BIAL is an international pharmaceutical group with own research that sells various products in over 50 countries on four continents. BIAL is the largest Portuguese pharmaceutical group. In Spain BIAL centralizes antiallergic vaccines and production means of diagnostics for allergies for the different markets where it operates. The Centre of excellence located in Bilbao, where the Group concentrated I & D projects in the area of allergic immunotherapy, is responsible for increasing the portfolio of products offers the pharmaceutical for the treatment of allergies.

The BIAL group is a partner of choice for many companies in response to its strong presence in the Iberian Peninsula, as well as in Latin America and in several countries of French- and Portuguese-speaking Africa.

BIAL is strongly committed to the therapeutic innovation, investing more than 20% of its annual turnover in I & D. The main areas of research and development of the company are the Central nervous system, Cardiovascular System and allergic immunotherapy. The recent launch of Zebinix ® now enables the presence of the BIAL group, through a business partner in various European countries, among which are large markets pharmacists, case of Germany and United Kingdom. Currently BIAL has other innovative products in development that will probably reach the market in the next few years consolidating the position of the company in Europe.

About Eisai

Eisai is a leading r & d globally-based pharmaceutical companies and has defined its corporate mission as “think first in patients and their families and increase the benefits provided by health care,” which we call human health care or Human HealthCare (hhc)(, for its acronym in English).

Eisai focuses its r & d activities in three key areas:

-area of Neuroscience: Alzheimer’s, multiple sclerosis, pain, epilepsy, depression, neuropathic, etc.

-Area of Oncology: cancer treatments; tumour-regressing, tumor suppression, antibodies, etc. and support cancer treatments; relief of pain, nausea, etc.

-Reaction vascular and immune and includes: acute coronary syndrome, disease concurrence, sepsis, psoriasis, rheumatoid arthritis, disease Crohn, etc.

Eisai, which develops its activity in the United States.USA, Asia, Europe and Japan, has over 11,000 employees working throughout the world.

Eisai has subsidiaries in Europe, in over 20 countries: United Kingdom, France, Germany, Italy, Spain, Switzerland, Sweden, Ireland, Austria, Denmark, Finland, Norway, Portugal, Iceland, Czech Republic, Hungary and Slovakia.

Referencia:

(1) report FEEN on epilepsy in Spain. Spanish Foundation of neurological diseases.

(2) Technical specifications of Zebinix ®, November 2010.

(3) (C) et Elger to the. Efficacy and Safety of Eslicarbazepine Acetate as Adjunctive Treatment in Adults with Refractory Partial-Onset Seizures: A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Phase III Study. Epilepsy 2009; 50 (3): 454 – 463.

Read More

Surah Al-Rehman – The Ultimate Free Remedy for Incurable Diseases

(By Listening Only- 20 Minutes Only)

Kindly download the Surah “AL-REHMAN” (recited by Qari Abdul Basit without translation) from here.


Treatment Plan

Just Listen to it three times a day (morning, afternoon, evening) for seven consecutive days using following procedure:-


    Before listening:

  • Close your eyes
  • Feel your self in front of ALLAH Almighty/ God
  • Then listen to it with greater concentration and closed eyes

    When the recitation/ AUDIO is finished:

  • Open your eyes and take half glass of water
  • Close your eyes again and say “ALLAH” three times in your heart with deep affection/ love
  • Then drink the water with closed eyes in three sips

Surah Al-Rehman – The Ultimate Free Remedy for Incurable Diseases

(By Listening Only- 20 Minutes Only)

Kindly download the Surah “AL-REHMAN” (recited by Qari Abdul Basit without translation) from here.


Treatment Plan

Just Listen to it three times a day (morning, afternoon, evening) for seven consecutive days using following procedure:-


    Before listening:

  • Close your eyes
  • Feel your self in front of ALLAH Almighty/ God
  • Then listen to it with greater concentration and closed eyes

    When the recitation/ AUDIO is finished:

  • Open your eyes and take half glass of water
  • Close your eyes again and say “ALLAH” three times in your heart with deep affection/ love
  • Then drink the water with closed eyes in three sips